Opus Genetics (IRD) Non-Current Debt (2025 - 2026)

Opus Genetics' (IRD) quarterly Non-Current Debt came in at $1.2 million in Q1 2026, up 6.11% on a QoQ basis from $1.1 million in Q4 2025.

Opus Genetics (IRD) Non-Current Debt (2025 - 2026) Analysis & Trends

Opus Genetics (IRD) has 2 years of Non-Current Debt data on file, last reported at $1.2 million in Q1 2026.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.1 million, changed N/A from the prior year.
Non-Current Debt for Q1 2026 stood at $1.2 million, up from $1.1 million in the prior quarter.
Over the last five years, Non-Current Debt for IRD reached as high as $1.2 million in Q1 2026 and fell as low as $1.0 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Opus Genetics	3.27 Mn	-56.73 Mn	-	1.20 Mn

Download Data